As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.
"This contract highlights Oxford Genetics' commitment to providing the highest quality cell line engineering services to its global customer base and continuing to add value to their operations," said Ryan Cawood, chief executive officer, Oxford Genetics. "We have moved away from manual processing, which is the norm in this market, in favor of automated, scalable platforms. This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need. We are excited about this project which will see us significantly expand our product portfolio and continue to deliver innovative products and solutions to the pharmaceutical industry."
Headquartered in Oxford, UK, Oxford Genetics is a synthetic biology company dedicated to developing and delivering technologies and services to its customers that will help to change the gene editing industry. The company's use of automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.